I'm LongbridgeAI, I can summarize articles.CervoMed presented new Phase 2b data at AAIC 2026 supporting a 50 mg three-times-daily dose of neflamapimod for its planned Phase 3 trial in dementia with Lewy bodies (DLB). Results indicated clinical benefits, particularly in 'pure' DLB patients with low pTau181 levels, showing reduced cognitive decline and slowed brain atrophy. Additionally, an open-label study confirmed the safety and tolerability of an 80 mg twice-daily regimen.
- CervoMed presented new AAIC 2026 analyses supporting 50 mg three-times-daily neflamapimod as the planned Phase 3 dose in dementia with Lewy bodies. * Exploratory RewinD-LB results linked benefit to “pure” DLB patients with plasma pTau181 <21 pg/mL and trough concentrations near 4 ng/mL. * Extension data showed better CDR-SB change with higher-exposure capsules: 0.17 worsening vs 0.95 on prior placebo in the same patients (p=0.005). * MRI analyses showed slowed right basal forebrain atrophy over 48 weeks, with increased basal forebrain–default mode network connectivity during the extension. * An open-label Phase 2 study of 80 mg twice daily met safety, tolerability, and pharmacokinetic goals over 24 weeks in 26 patients. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here